TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

被引：0
|
作者：
Jakobsen, Jan Nyrop [1 ]
Urup, Thomas [1 ]
Grunnet, Kirsten [1 ,2 ]
Christensen, Ib Jarle [3 ]
Villingshoj, Mette [2 ]
Poulsen, Hans Skovgaard [1 ,2 ]
机构：
[1] Rigshosp, Dept Oncol, Copenhagen, Denmark
[2] Rigshosp, Dept Radiat Biol, Copenhagen, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Lab Gastroenterol, Copenhagen, Denmark
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ACTR-26
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
    Jakobsen, J. N.
    Urup, T.
    Grunnet, K.
    Toft, A.
    Johansen, M. D.
    Poulsen, S. H.
    Christensen, I. J.
    Muhic, A.
    Poulsen, H. S.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 439 - 446
  • [2] Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
    J. N. Jakobsen
    T. Urup
    K. Grunnet
    A. Toft
    M. D. Johansen
    S. H. Poulsen
    I. J. Christensen
    A. Muhic
    H. S. Poulsen
    [J]. Journal of Neuro-Oncology, 2018, 137 : 439 - 446
  • [3] Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
    Simoes, J.
    Tavares, N. T.
    Borges, C.
    Meireles, S.
    Fernandes, C.
    Costa, A.
    Caeiro, C.
    Damasceno, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
    Taal, Walter
    Oosterkamp, Hendrika M.
    Walenkamp, Annemiek M. E.
    Dubbink, Hendrikus J.
    Beerepoot, Laurens V.
    Hanse, Monique C. J.
    Buter, Jan
    Honkoop, Aafke H.
    Boerman, Dolf
    de Vos, Filip Y. F.
    Dinjens, Winand N. M.
    Enting, Roelien H.
    Taphoorn, Martin J. B.
    van den Berkmortel, Franchette W. P. J.
    Jansen, Rob L. H.
    Brandsma, Dieta
    Bromberg, Jacoline E. C.
    van Heuvel, Irene
    Vernhout, Rene M.
    van der Holt, Bronno
    van den Bent, Martin J.
    [J]. LANCET ONCOLOGY, 2014, 15 (09): : 943 - 953
  • [5] The efficacy and toxicity of bevacizumab plus genicitabine in patients with recurrent ovarian cancer
    Bevis, K. S.
    Numnum, T. M.
    Shipman, K. A.
    Makhija, S.
    Barnes, M. N.
    Straughn, J.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S119 - S120
  • [6] Addition of lomustine for bevacizumab-refractory recurrent glioblastoma
    Tonder, Michaela
    Eisele, Guenter
    Weiss, Tobias
    Hofer, Silvia
    Seystahl, Katharina
    Valavanis, Antonios
    Stupp, Roger
    Weller, Michael
    Roth, Patrick
    [J]. ACTA ONCOLOGICA, 2014, 53 (10) : 1436 - +
  • [7] A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
    Taal, Walter
    Oosterkamp, Hendrika M.
    Walenkamp, Annemiek M. E.
    Beerepoot, Laurens Victor
    Hanse, Monique
    Buter, J.
    Honkoop, Aafke
    Boerman, Dolf
    De Vos, Filip Yves Francine Leon
    Jansen, Rob L.
    van den Berkmortel, Franchette W. P. J.
    Brandsma, Dieta
    Kros, Johan M.
    Bromberg, Jacoline E.
    van Heuvel, Irene
    Smits, Marion
    van der Holt, Bronno
    Vernhout, Rene
    Van den Bent, Martin J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
    Rahman, Rifaquat
    Hempfling, Kelly
    Norden, Andrew D.
    Reardon, David A.
    Nayak, Lakshmi
    Rinne, Mikael L.
    Beroukhim, Rameen
    Doherty, Lisa
    Ruland, Sandra
    Rai, Arun
    Rifenburg, Jennifer
    LaFrankie, Debra
    Alexander, Brian M.
    Huang, Raymond Y.
    Wen, Patrick Y.
    Lee, Eudocia Q.
    [J]. NEURO-ONCOLOGY, 2014, 16 (11) : 1523 - 1529
  • [9] Bevacizumab plus irinotecan in recurrent glioblastoma
    Chamberlain, Marc C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 1012 - 1013
  • [10] TOXICITY OF COMBINED BEVACIZUMAB-LOMUSTINE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): REPORT FROM A RANDOMIZED PHASE II STUDY
    van den Bent, Martin
    Taal, Walter
    Sleijfer, Stefan
    van Heuvel, Irene
    SillevisSmitt, Peter A.
    Bromberg, Jacoline E.
    Vernhout, Irene
    [J]. NEURO-ONCOLOGY, 2010, 12 : 42 - 42
12345